BioCentury | Apr 6, 2009
Company News

Axikin, Proteros deal

...and use its X-ray crystallography to determine the structure of an undisclosed protein provided by Axikin...
...crystallography to determine the binding mode of fragments and identify candidates to treat inflammatory diseases. Axikin...
...identified. Proteros is eligible for undisclosed research fees and milestones. Further terms were not disclosed. Axikin Pharmaceuticals Inc....
BioCentury | Feb 9, 2009
Company News

Actimis Pharmaceuticals pulmonary, inflammation news

...Actimis completed its previously announced spinout of Axikin Pharmaceuticals Inc. to develop four undisclosed preclinical small molecules to...
Items per page:
1 - 2 of 2
BioCentury | Apr 6, 2009
Company News

Axikin, Proteros deal

...and use its X-ray crystallography to determine the structure of an undisclosed protein provided by Axikin...
...crystallography to determine the binding mode of fragments and identify candidates to treat inflammatory diseases. Axikin...
...identified. Proteros is eligible for undisclosed research fees and milestones. Further terms were not disclosed. Axikin Pharmaceuticals Inc....
BioCentury | Feb 9, 2009
Company News

Actimis Pharmaceuticals pulmonary, inflammation news

...Actimis completed its previously announced spinout of Axikin Pharmaceuticals Inc. to develop four undisclosed preclinical small molecules to...
Items per page:
1 - 2 of 2